{"id":2305,"date":"2019-05-17T23:37:37","date_gmt":"2019-05-17T23:37:37","guid":{"rendered":"http:\/\/entrogen.com\/web4\/?page_id=2305"},"modified":"2021-10-04T18:02:33","modified_gmt":"2021-10-04T18:02:33","slug":"idh-12-mutation-detection-kit","status":"publish","type":"page","link":"https:\/\/entrogen.com\/web4\/idh-12-mutation-detection-kit\/","title":{"rendered":"IDH1\/2 Mutation Detection Kit"},"content":{"rendered":"[et_pb_section fullwidth=”on” specialty=”off”][et_pb_fullwidth_header admin_label=”Fullwidth Header” title=”IDH1\/2 Mutation Detection Kit” background_layout=”dark” text_orientation=”left” module_class=”product-page-header” \/][\/et_pb_section][et_pb_section][et_pb_row][et_pb_column type=”2_3″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left”]\n

 <\/p>\n

\n
\n
\n\n\n\n\n
Product Name\/Description <\/strong><\/th>\n\n
No. of Reactions*<\/strong><\/div>\n<\/th>\n
Product Code <\/strong><\/th>\n<\/tr>\n
IDH1\/2 Mutation Detection Kit<\/td>\n\n
38<\/div>\n<\/td>\n
IDH-RT38<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

*Includes all controls.<\/p>\n

 <\/p>\n<\/div>\n<\/div>\n<\/div>\n

IDH1\/2 Mutations and Cancer<\/h3>\n

Isocitrate dehydrogenase 1 and 2 (IDH1\/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. Mutations in IDH1\/2<\/em> can lead to the development and\/or progression of various types of cancer including secondary glioblastomas and acute myeloid leukemias (AML).\u00a0 IDH1\/2 mutations are linked to abnormal histone and DNA methylation which may cause altered stem cell differentiation and eventual tumorigenesis. The unique features of IDH1\/2 mutations make them good biomarkers and promising drug targets.<\/p>\n

Glioblastoma
\n<\/strong><\/span>
\nIDH 1\/2 mutations have been identified mostly in secondary GBM and recently shown to carry strong favorable prognostic significance. Furthermore, evidence shows that IDH mutations are tightly associated with MGMT promoter methylation. MGMT promoter methylation leads to increased sensitivity to alkylating agents, such as temozolomide, and has prognostic significance similar to IDH mutations.\u00a0 IDH1\/2 mutations are prognostic in GBM and are associated with a better outcome than IDH1\/2-negative GBM.<\/p>\n

Acute Myeloid Leukemia (AML)
\n<\/strong><\/span><\/p>\n

IDH1\/2 mutations are found in approximately 20% of AML patients.\u00a0 Mutations in the IDH1\/2 genes are known to disrupt several cell processes which ultimately prevents bone marrow cells from maturing properly.\u00a0 IDH inhibitors are designed to help leukemia cells mature into normal blood cells.\u00a0 Some of these drugs, such as enasidenib (Idhifa)\u00a0and ivosidenib (Tibsovo), are now approved to treat AML with certain\u00a0IDH<\/em>\u00a0gene mutations.<\/p>\n

 <\/p>\n

Kit Features<\/h3>\n

The IDH 1\/2 assay is polymerase chain reaction (PCR)-based that detects somatic mutations in DNA isolated from blood or tissue in three multiplexed reactions.\u00a0 It works by amplifying mutant-specific sequences in DNA samples. Each kit is supplied with primer\/probe sets for multiplexed detection of both target and internal control genes.<\/p>\n

 <\/p>\n

Detected Mutations<\/h3>\n

The IDH1\/2 Mutation Detection Kit is intended for the detection of IDH1 and IDH2 somatic mutations in genomic DNA isolated from human tissue.<\/p>\n

List of IDH mutations detected by this kit:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Gene<\/strong><\/td>\nExon<\/strong><\/td>\naa change<\/strong><\/td>\nnt change<\/strong><\/td>\nCosmic ID<\/strong><\/td>\nDetected by Primer No.<\/strong><\/td>\n<\/tr>\n
IDH1<\/td>\n4<\/td>\nR132H<\/td>\nc.395G>A<\/td>\nCOSM28746<\/td>\n1<\/td>\n<\/tr>\n
R132C<\/td>\nc.394C>T<\/td>\nCOSM28747<\/td>\n<\/tr>\n
R132S<\/td>\nc.394C>A<\/td>\nCOSM28748<\/td>\n<\/tr>\n
R132G<\/td>\nc.394C>G<\/td>\nCOSM28749<\/td>\n<\/tr>\n
R132L<\/td>\nc.395G>T<\/td>\nCOSM28750<\/td>\n<\/tr>\n
R132P<\/td>\nc.395G>C<\/td>\nCOSM221574<\/td>\n<\/tr>\n
R132V<\/td>\nc.394_395CG>GT<\/td>\nCOSM28751<\/td>\n<\/tr>\n
R100Q<\/td>\nc.299G>A<\/td>\nCOSM88208<\/td>\n2<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
Gene<\/strong><\/td>\nExon<\/strong><\/td>\naa change<\/strong><\/td>\nnt change<\/strong><\/td>\nCosmic ID<\/strong><\/td>\nDetected by Primer No.<\/strong><\/td>\n<\/tr>\n
IDH2<\/td>\n4<\/td>\nR172K<\/td>\nc.515G>A<\/td>\nCOSM33733<\/td>\n3<\/td>\n<\/tr>\n
R172M<\/td>\nc.515G>T<\/td>\nCOSM33732<\/td>\n<\/tr>\n
R172W<\/td>\nc.514A>T<\/td>\nCOSM34039<\/td>\n<\/tr>\n
R172G<\/td>\nc.514A>G<\/td>\nCOSM33731<\/td>\n<\/tr>\n
R172S<\/td>\nc.516G>T<\/td>\nCOSM34090<\/td>\n<\/tr>\n
R140Q<\/td>\nc.419G>A<\/td>\nCOSM41590<\/td>\n4<\/td>\n<\/tr>\n
R140W<\/td>\nc.418C>T<\/td>\nCOSM41877<\/td>\n<\/tr>\n
R140L<\/td>\nc.419G>T<\/td>\nCOSM41875<\/td>\n5<\/td>\n<\/tr>\n
R140G<\/td>\nc.418C>G<\/td>\nCOSM1737874<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/strong><\/p>\n

Testing Procedure and Analysis<\/h3>\n

The testing procedure involves the following simple steps:<\/p>\n

    \n
  1. Isolation of DNA from tumor biopsies, paraffin-embedded sections (FFPE), fresh frozen tumors or blood.<\/li>\n
  2. Set up PCR reaction using reagents provided in the kit.<\/li>\n
  3. Run assay on real-time PCR instrument.<\/li>\n
  4. Data analysis and interpretation using real-time PCR software.<\/li>\n<\/ol>\n

     <\/p>\n

    Equipment & Materials<\/h3>\n

    EntroGen\u2019s IDH1\/2 assay requires a real-time PCR instrument capable of detecting FAM and VIC fluorescent probes.<\/p>\n

    The test includes reagents required for PCR amplification\/detection, as well as validated reaction controls. Columns and reagents for DNA isolation are not included.<\/p>\n

     <\/p>\n

    Intended Use<\/h3>\n

    USA: <\/strong>EntroGen\u2019s IDH1\/2 assay is provided for research use only (RUO)<\/strong>. Not for use in diagnostic procedures.<\/p>\n

    Europe:\u00a0<\/strong>EntroGen\u2019s IDH1\/2 assay is available for research<\/strong> (RUO<\/strong>) and diagnostic (CE-IVD)<\/strong> purposes.<\/p>\n

     <\/p>\n

    Bibliography of studies using this product<\/h3>\n

    Prognostic and Predictive Biomarkers in Gliomas.<\/strong> \u015aledzi\u0144ska P, Bebyn MG, Furtak J, Kowalewski J, <\/span>Lewandowska MA. Special Issue:\u00a0 Biomolecular Characterization of Brain Gliomas and Molecular Alterations Caused by Therapy. International Journal of Molecular Sciences. 2021, 22<\/em>(19), 10373;\u00a0 DOI.org ID<\/a>.<\/p>\n

    <\/h4>\n[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left”]\n

    <\/p>\n

    \n
    \n

    More Product Info<\/h2>\n
    \n
    Request Additional Information<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n

    <\/p>\n

    <\/div>\n
    \n
    \n
    \n
    \n

    Related Products<\/h2>\n
    \n